International
The Morning Science

What science found today

‹
 

Research

Experimental antibody-drug conjugate shows promising initial activity in head and neck cancers

Medical Xpress ·

Experimental antibody-drug conjugate shows promising initial activity in head and neck cancers

The Brief

  • A Phase I trial of the investigational antibody-drug conjugate micvotabart pelidotin (MICVO, PYX-201) showed promising antitumor activity in head and neck cancers.
  • The trial reported a manageable safety profile.
  • The results were presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.

Why it matters

This is early-stage evidence from a Phase I trial, so it shows initial activity and safety rather than efficacy, and science readers should watch for later-phase results before drawing conclusions about treatment benefit.

Who’s affected

  • oncologists and head and neck cancer researchers
  • drug developers working on antibody-drug conjugates

The investigational antibody-drug conjugate (ADC) micvotabart pelidotin (MICVO, PYX-201) demonstrated promising antitumor activity and a manageable safety profile in a Phase I trial presented at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics by…

How do you feel about this?

0 Comments

    Experimental antibody-drug conjugate shows promising initial activity in head and neck cancers – The Morning Science